Try our Advanced Search for more refined results

Phigenix, Inc. v. Genentech, Inc.

  1. November 27, 2018

    Phigenix Fights $2.2M Atty Fee Bid In Cancer Drug IP Row

    Phigenix Inc. is fighting Genentech Inc.'s request for more than $2.2 million in attorneys' fees after beating a patent infringement suit in California federal court over the breast cancer drug Kadcyla.

  2. August 13, 2018

    After 'Untenable' IP Case, Judge Says MoFo Is Owed Fees

    A California federal judge on Monday sided with a team of Morrison & Foerster LLP attorneys who helped Genentech Inc. beat a patent infringement suit by Phigenix Inc. over the breast cancer drug Kadcyla, granting attorneys' fees after finding Phigenix had "stubbornly proceeded with an untenable case."

  3. August 18, 2017

    Genentech Beats IP Suit Over Breast Cancer Drug Patent

    A California federal judge on Thursday tossed Phigenix Inc.'s patent infringement suit against Genentech Inc. over a breast cancer drug, finding no evidence that Genentech encouraged health care professionals to administer Kadcycla to a narrow subclass of patients or even knew they existed.

  4. August 03, 2017

    Genentech Says IP Suit Should End After Phigenix Attys Leave

    Genentech Inc. told a California federal judge Thursday that it will move to end Phigenix Inc.'s patent infringement suit over a breast cancer drug after the judge allowed Phigenix's attorneys to withdraw over the company's failure to timely pay its legal bills.

  5. January 05, 2017

    Genentech Presses For Cancer Drug Patent's Invalidation

    Genentech Inc. urged a California federal judge on Thursday to invalidate a patent at the center of Phigenix Inc.'s infringement suit targeting Genetech's breast cancer treatment Kadcyla, arguing the patent's claims were anticipated by earlier clinical trials and are "infinitely broad."

  6. May 11, 2016

    Genentech Asks For Sanctions In Kadcyla Patent Suit

    Genentech Inc. asked a California federal judge Tuesday to throw out a patent lawsuit targeting its breast cancer treatment drug Kadcyla and sanction the Atlanta research company that filed the case, arguing the infringement claims were "scientifically unsupportable."